IBSA at the AME conference: innovation at the service of endocrinology12 November 2019
For the treatment of hypothyroidism, patients prefer to take levothyroxine with innovative formulations compared to traditional tablets. This is what emerged from a session entitled ‘Studio ETA sulla terapia sostitutiva dell'ipotiroidismo: come si comporta l’Italia’ (ETA study on replacement therapy for hypothyroidism: how Italy behaves), held by Dr R. Negro during the recent Congresso dei Medici Endocrinologi endocrinologists’ conference held in Rome from 7 to 10 November. IBSA is at the forefront in this field and is in fact the first company to have marketed this active ingredient in liquid form and in soft-gel capsules.
But the innovation does not end there: in the second symposium on the main theme of erectile dysfunction, held by Dr Castello and Dr Giagulli, it was stressed that the new ODF formulation of sildenafil is a plus for patients, both in terms of its ease of use and its innovative formulation, which is different from a tablet.
IBSA was present throughout the conference with a stand dedicated to endocrinology, infertility and urology products. It also offered a space to the Meteda company for the presentation of the endocrinological chart already existing in many diabetology departments, extended also to patients with thyroid problems.